Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma

被引:8
|
作者
Cioffi, Angela [2 ]
Italiano, Antoine [1 ]
机构
[1] Inst Bergonie, F-33076 Bordeaux, France
[2] Inst Gustave Roussy, Villejuif, France
关键词
chemotherapy; ecteinascidin; ERCC5; ET-743; sarcoma; trabectedin; PHASE-II; ECTEINASCIDIN-743; ET-743; ANTITUMOR-ACTIVITY; EUROPEAN ORGANIZATION; MYXOID LIPOSARCOMAS; NUCLEOTIDE-EXCISION; UNIQUE MECHANISM; MARINE COMPOUND; CHEMOTHERAPY; CANCER;
D O I
10.1517/17425255.2012.636353
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Forty percent of patients with soft-tissue sarcoma (STS) will develop metastatic disease. Furthermore, up until 2007, doxorubicin and ifosfamide were the only drugs approved for the treatment of patients with advanced STS. In addition to the lack of available drugs on the market, there was a distinct lack of alternative options for patients who had first-line doxorubicin-based chemotherapy failure even though more than 40 different drugs have been investigated in this setting over the past three decades. In 2007, trabectedin received European approval for patients with advanced or metastatic STS who had either failed with or were unsuitable for first-line therapy with anthracyclines and ifosfamide, either sequentially or in combination. Areas covered: The article was based on a literature search performed through PubMed for papers published between January, 2000, and June, 2011, using the search terms 'trabectedin,' 'ET-743' and 'ecteinascidin'. Expert opinion: Despite an objective response rate lower than 10%, trabectedin met the European Organisation for the Research and Treatment of Cancer criteria, in terms of non-progression rate, to be considered as an active drug in advanced STS after failure of standard first-line chemotherapy. The authors believe that further biological and clinical studies are needed in order for clinicians to be able to identify patients who are more likely to benefit from the administration of this drug.
引用
收藏
页码:113 / 122
页数:10
相关论文
共 50 条
  • [21] Olaratumab for the treatment of soft-tissue sarcoma
    Pender, Alexandra
    Jones, Robin L.
    FUTURE ONCOLOGY, 2017, 13 (24) : 2151 - 2157
  • [22] TREATMENT OF SOFT-TISSUE SARCOMA BY CHEMOTHERAPY
    KREMENTZ, ET
    SHAVER, JO
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1963, 184 (02): : 149 - &
  • [23] Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
    Sessa, C.
    Perotti, A.
    Noberasco, C.
    De Braud, F.
    Gallerani, E.
    Cresta, S.
    Zucchetti, M.
    Vigano, L.
    Locatelli, A.
    Jimeno, J.
    Feilchenfeldt, J. W.
    D'Incalci, M.
    Capri, G.
    Ielmini, N.
    Gianni, L.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (07) : 1153 - 1161
  • [24] ERCC5 (XPG) status and clinical activity of trabectedin in patients with advanced soft-tissue sarcoma
    Italiano, Antoine
    Laurand, Armelle
    Moisan, Francois
    Robert, Jacques
    Ray-Coquard, Isabelle
    Blay, Jean-Yves
    Bui, Binh
    Coindre, Jean-Michel
    Benlloch, Susana
    Tercero, Juan-Carlos
    Pourquier, Philippe
    CANCER RESEARCH, 2010, 70
  • [25] Phase I and pharmacokinetic study of trabectedin in Japanese patients with soft tissue sarcoma
    Yonemori, K.
    Ueda, T.
    Sugiura, H.
    Kawai, A.
    Ando, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S888 - S889
  • [26] Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
    Blay, Jean-Yves
    von Mehren, Margaret
    Samuels, Brian L.
    Fanucchi, Michael P.
    Ray-Coquard, Isabelle
    Buckley, Brigid
    Gilles, Leen
    Lebedinsk, Claudia
    Elsayed, Yusri A.
    Le Cesne, Axel
    CLINICAL CANCER RESEARCH, 2008, 14 (20) : 6656 - 6662
  • [27] Trabectedin (Yondelis®) in Soft Tissue Sarcoma
    Zintl, Patrik
    Santabarbara, Pedro
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 29 - 31
  • [28] The Role of Trabectedin in Soft Tissue Sarcoma
    Nakamura, Tomoki
    Sudo, Akihiro
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [29] TREATMENT OF SOFT-TISSUE SARCOMA IN CHILDHOOD AND ADOLESCENCE - A REPORT OF THE GERMAN COOPERATIVE SOFT-TISSUE SARCOMA STUDY
    KOSCIELNIAK, E
    JURGENS, H
    WINKLER, K
    BURGER, D
    HERBST, M
    KEIM, M
    BERNHARD, G
    TREUNER, J
    CANCER, 1992, 70 (10) : 2557 - 2567
  • [30] STAGING SYSTEM FOR SOFT-TISSUE SARCOMA AND ITS EVALUATION IN RELATION TO TREATMENT
    TOMITA, Y
    KURATSU, S
    NAKA, N
    UCHIDA, A
    ONO, K
    OHSAWA, M
    AOZASA, K
    INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (02) : 168 - 173